Pipobroman

Pipobroman

SCHEMBL4889

O=C(CCBr)N1CCN(C(=O)CCBr)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 1.00
KMT2A Q03164 3/20 1.00
LMNA P02545 3/20 1.00
ALDH1A1 P00352 2/20 1.00
TDP1 Q9NUW8 2/20 1.00
HSD17B10 Q99714 2/20 1.00
KDM4E B2RXH2 1/20 1.00
USP2 O75604 1/20 1.00
CYP3A4 P08684 1/20 1.00
HPGD P15428 1/20 1.00
ATM Q13315 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.41
NPC1 O15118 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
GNAI3 P08754 1/20 0.39
GNAI1 P63096 1/20 0.39
TSHR P16473 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pipobroman SCHEMBL2351497 1.00 MEN1 (1.00) MEN1KMT2ALMNAALDH1A1TDP1
SCHEMBL20985713 0.90 ALDH1A1 (0.81) MEN1KMT2ALMNAALDH1A1TDP1
SCHEMBL14608859 0.89 MEN1 (0.78) MEN1KMT2ALMNAALDH1A1TDP1
Pipobroman SCHEMBL28257773 0.89 ALDH1A1 (0.78) MEN1KMT2ALMNAALDH1A1TDP1
SCHEMBL13478125 0.89 MEN1 (0.78) MEN1KMT2ALMNAALDH1A1TDP1
SCHEMBL16093106 0.87 ALDH1A1 (0.77) MEN1KMT2ALMNAALDH1A1TDP1
Hydrochloric Acid SCHEMBL27088452 0.87 KMT2A (0.75) MEN1KMT2ALMNAALDH1A1TDP1
SCHEMBL9674149 0.85 LMNA (0.72) MEN1KMT2ALMNAALDH1A1TDP1
SCHEMBL5490325 0.84 ALDH1A1 (0.71) MEN1KMT2ALMNAALDH1A1TDP1
SCHEMBL27088455 0.84 HSD17B10 (0.71) MEN1KMT2ALMNAALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 51412 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4748859-A2 CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF The Regents of the University of California (US) 2026-05-27 EP claimed
US-20260137794-A1 LIGAND-DRUG CONJUGATE AND USE THEREOF SYSTIMMUNE INC (US) 2026-05-21 US claimed
EP-4743490-A1 HUMANIZED ANTI-CD7 ANTIBODY Christian-Albrechts-Universität zu Kiel (DE) 2026-05-20 EP claimed
CN-122056884-A Methods of treating pancreatic cancer 坎莫森特里克斯公司 2026-05-19 CN claimed
WO-2026099502-A1 NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2026-05-15 WO claimed
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
US-20260108476-A1 2,4 DNP and Prodrugs Thereof for Treatment of Cancer MITOCHON PHARMACEUTICALS, INC. (US) 2026-04-23 US claimed
EP-4729063-A2 TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES BPGbio, Inc. (US) 2026-04-22 EP claimed
US-20260091119-A1 ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA CELLIS AG (CH) 2026-04-02 US claimed
EP-0912738-A2 ANTIGEN BINDING FRAGMENTS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS Novopharm Biotech, Inc. (CA) 1999-05-06 EP claimed
WO-1999001118-A2 ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS ATHEROGENICS, INC. (US) 1999-01-14 WO claimed
WO-1998020140-A9 ISOLATED TUMOR NECROSIS FACTOR RECEPTOR RELEASING ENZYME, COMPOSITIONS COMPRISING THE ENZYME AND METHODS OF THE USE THEREOF 1998-08-20 WO claimed
WO-1998020140-A1 ISOLATED TUMOR NECROSIS FACTOR RECEPTOR RELEASING ENZYME, COMPOSITIONS COMPRISING THE ENZYME AND METHODS OF THE USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-05-14 WO claimed
WO-1997046531-A1 PYRIDINE DERIVATIVE, COMPOSITION AND METHOD FOR TREATING CANCER THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1997-12-11 WO claimed
WO-1997044461-A2 ANTIGEN BINDING FRAGMENTS THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS NOVOPHARM BIOTECH, INC. (CA) 1997-11-27 WO claimed
WO-1997042980-A1 METHODS OF TERMINAL STERILIZATION OF BIOLOGICAL PRODUCTS QUADRANT HOLDINGS CAMBRIDGE LIMITED (GB) 1997-11-20 WO claimed
US-5288503-A WATER-PERMEABLE DIFFUSION BARRIER OF POLYVINYL ALCOHOL SRCHEM INCORPORATED (US) 1994-02-22 US claimed
US-5260066-A Cryogel bandage containing therapeutic agent SRCHEM INCORPORATED (US) 1993-11-09 US claimed
EP-0010964-A1 Ravidomycin, process of preparation and pharmaceutical compositions containing same AYERST, MCKENNA AND HARRISON INC. (CA) 1980-05-14 EP claimed